|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vire E, Brenner C, Deplus R, Blanchon L,
Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden
JM, et al: The Polycomb group protein EZH2 directly controls DNA
methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee TI, Jenner RG, Boyer LA, Guenther MG,
Levine SS, Kumar RM, et al: Control of developmental regulators by
polycomb in human embryonic stem cells. Cell. 125:301–313. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ezhkova E, Pasolli HA, Parker JS, Stokes
N, Su IH, Hannon G, Tarakhovsky A and Fuchs E: Ezh2 orchestrates
gene expression for the stepwise differentiation of tissue-specific
stem cells. Cell. 136:1122–1135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li KQ, Liu C, Zhou BF, Bi L, Huang H, Lin
T and Xu K: Role of EZH2 in the growth of prostate cancer stem
cells isolated from LNCaP cells. Int J Mol Sci. 14:11981–11993.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rizzo S, Hersey JM, Mellor P, Dai W,
Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson
DL, Kaye SB and Brown R: Ovarian cancer stem cell-like side
populations are enriched following chemotherapy and overexpress
EZH2. Mol Cancer Ther. 10:325–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sobin LH, Gospodarowicz MK and Wittekind
C: UICC TNM classification of malignant tumours (7th).
Wiley-Blackwell. Oxford: 63–72. 2009.
|
|
9
|
Shi Y, Gong HL, Zhou L, Tian J and Wang Y:
CD24: A novel cancer biomarker in laryngeal squamous cell
carcinoma. ORL J Otorhinolaryngol Relat Spec. 74:78–85. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao LB, Yu Y, Wu J, Bai J, Zhao Y, Li C,
Sun W and Wang X: Role of EZH2 in oral squamous cell carcinoma
carcinogenesis. Gene. 537:197–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blake JL, Runhua S, Vikas M, Glenn M,
Federico A and Cherie-Ann ON: Improvements in survival and
disparities for advanced-staged laryngeal cancer. JAMA Otolaryngol
Head Neck Surg. 141:169–173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kamminga LM, Bystrykh LV, de Boer A,
Houwer S, Douma J, Weersing E, Dontje B and de Haan G: The polycomb
group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood.
107:2170–2179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Juan AH, Derfoul A, Feng X, Ryall JG,
Dell'Orso S, Pasut A, Zare H, Simone JM, Rudnicki MA and Sartorelli
V: Polycomb EZH2 controls self-renewal and safeguards the
transcriptional identity of skeletal muscle stem cells. Gene Dev.
25:789–794. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sher F, Rössler R, Brouwer N,
Balasubramaniyan V, Boddeke E and Copray S: Differentiation of
neural stem cells into oligodendrocytes: Involvement of the
polycomb group protein Ezh2. Stem Cells. 26:2875–2883. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gong Y, Huo L, Liu P, Sneige N, Sun X,
Ueno NT, Lucci A, Buchholz TA, Valero V and Cristofanilli M:
Polycomb group protein EZH2 is frequently expressed in inflammatory
breast cancer and is predictive of worse clinical outcome. Cancer.
117:5476–5484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wan L, Li X, Shen H and Bai X:
Quantitative analysis of EZH2 expression and its correlations with
lung cancer patients' clinical pathological characteristics. Clin
Transl Oncol. 15:132–138. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wagener N, Macher-Goeppinger S, Pritsch M,
Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp
A, Hoppe-Seyler F and Hohenfellner M: Enhancer of zeste homolog 2
(EZH2) expression is an independent prognostic factor in renal cell
carcinoma. Bmc Cancer. 10:5242010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bachmann IM, Halvorsen OJ, Collett K,
Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, et al:
EZH2 expression is associated with high proliferation rate and
aggressive tumor subgroups in cutaneous melanoma and cancers of the
endometrium, prostate and breast. J Clin Oncol. 24:268–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kidani K, Osaki M, Tamura T, Yamaga K,
Shomori K, Ryoke K and Ito H: High expression of EZH2 is associated
with tumor proliferation and prognosis in human oral squamous cell
carcinomas. Oral Oncol. 45:39–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alajez NM, Shi W, Hui AB, Bruce J,
Lenarduzzi M, Ito E, Yue S, O'Sullivan B and Liu F: Enhancer of
Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal
carcinoma and is regulated by miR-26a, miR-101 and miR-98. Cell
Death Dis. 1:e852010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rao ZY, Cai MY, Yang GF, He LR, Mai SJ,
Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, et al: EZH2 supports
ovarian carcinoma cell invasion and/or metastasis via regulation of
TGF-beta1 and is a predictor of outcome in ovarian carcinoma
patients. Carcinogenesis. 31:1576–1583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ,
Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, et al: EZH2 supports
nasopharyngeal carcinoma cell aggressiveness by forming a
co-repressor complex with HDAC1/HDAC2 and Snail to inhibit
E-cadherin. Oncogene. 31:583–594. 2012.PubMed/NCBI
|
|
23
|
Crea F, Fornaro L, Bocci G, Sun L, Farrar
WL, Falcone A and Danesi R: EZH2 inhibition: Targeting the
crossroad of tumor invasion and angiogenesis. Cancer Metast Rev.
31:753–761. 2012. View Article : Google Scholar
|
|
24
|
Chen H, Zhou L, Wan G, Dou T and Tian J:
BMI1 promotes the progression of laryngeal squamous cell carcinoma.
Oral Oncol. 47:472–481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suvà ML, Riggi N, Janiszewska M,
Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino
D, Cironi L, et al: EZH2 Is Essential for glioblastoma cancer stem
cell maintenance. Cancer Res. 69:9211–9218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Majewski IJ, Blewitt ME, de Graaf CA,
McManus EJ, Bahlo M, Hilton AA, Hyland CD, Smyth GK, Corbin JE,
Metcalf D, et al: Polycomb repressive complex 2 (PRC2) restricts
hematopoietic stem cell activity. PLoS Biol. 6:e932008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van Vlerken LE, Kiefer CM, Morehouse C, Li
Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE and Hurt EM: EZH2
is required for breast and pancreatic cancer stem cell maintenance
and can be used as a functional cancer stem cell reporter. Stem
Cells Transl Med. 2:43–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McCabe MT, Ott HM, Ganji G, Korenchuk S,
Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III,
Diaz E, et al: EZH2 inhibition as a therapeutic strategy for
lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sasaki H, Setoguchi T, Matsunoshita Y, Gao
H, Hirotsu M and Komiya S: The knock-down of overexpressed EZH2 and
BMI-1 does not prevent osteosarcoma growth. Oncol Rep. 23:677–684.
2010.PubMed/NCBI
|
|
30
|
Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee
YJ, Jiang X, Tan J, Aau M, Lim CZ and Yu Q: Polycomb protein EZH2
regulates cancer cell fate decision in response to DNA damage. Cell
Death Differ. 18:1771–1779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Q, Padi SK, Tindall DJ and Guo B:
Polycomb protein EZH2 suppresses apoptosis by silencing the
proapoptotic miR-31. Cell Death Dis. 5:e14862014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Serguei V and Xin W: Cancer stem cells and
drug resistance: The potential of nanomedicine. Nanomedicine.
7:597–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J,
Xiao L and Wang Z: Overexpression of EZH2 contributes to acquired
cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Cancer Biol Ther. 10:788–795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meng X, Huang Z, Wang R, Jiao Y, Li H, Xu
X, Feng R, Zhu K, Jiang S, Yan H and Yu J: The prognostic role of
EZH2 expression in rectal cancer patients treated with neoadjuvant
chemoradiotherapy. Radiat Oncol. 9:1882014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu CH, Han HD, Mangala LS, Ali-Fehmi R,
Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et
al: Regulation of tumor angiogenesis by EZH2. Cancer Cell.
18:185–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Benetatos L, Voulgaris E, Vartholomatos G
and Hatzimichael E: Non-coding RNAs and EZH2 interactions in
cancer: Long and short tales from the transcriptome. Int J Cancer.
133:267–274. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen H, Xin Y, Zhou L, Huang JM, Tao L,
Cheng L and Tian J: Cisplatin and paclitaxel target significant
long noncoding RNAs in laryngeal squamous cell carcinoma. Med
Oncol. 31:2462014. View Article : Google Scholar : PubMed/NCBI
|
